0000031462false0000031462us-gaap:CommonStockMember2024-02-132024-02-130000031462ecl:EuroNotesDue2025Member2024-02-132024-02-1300000314622024-02-132024-02-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 13, 2024

ECOLAB INC.

(Exact name of registrant as specified in its charter)

Delaware

1-9328

41-0231510

(State or other jurisdiction
of incorporation)

(Commission
File No.)

(IRS Employer
Identification No.)

1 Ecolab Place, Saint Paul, Minnesota

55102

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code 1-800-232-6522

(Not applicable)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $1.00 par value

ECL

New York Stock Exchange

2.625% Euro Notes due 2025

ECL 25

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On February 13, 2024, Ecolab Inc. (“Ecolab”) announced earnings for the fourth quarter ended December 31, 2023. A copy of the (i) News Release issued by Ecolab in connection with this report under Item 2.02 is furnished and attached as Exhibit (99.1) and (ii) Supplemental Data to be used in connection with the conference call to be held discussing the fourth quarter results is furnished and attached as Exhibit (99.2), each of which is incorporated by reference herein. Ecolab also will publish the attached exhibits on its website located at www.ecolab.com.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

The following exhibits are furnished pursuant to Item 2.02 of Form 8-K and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

Exhibit No.

Description

Method Of Filing

(99.1)

Ecolab Inc. News Release dated February 13, 2024.

Filed herewith electronically.

(99.2)

Supplemental Data for Fourth Quarter dated February 13, 2024.

Filed herewith electronically.

(104)

Cover Page Interactive Data File.

Embedded within the Inline XBRL document.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ECOLAB INC.

Date: February 13, 2024

By:

/s/ David F. Duvick

David F. Duvick

Assistant Secretary

3

Exhibit 99.1

Graphic

News Release

Investor Contact:

Media Contact:

Andrew Hedberg (651) 250-2185

Nigel Glennie (651) 250-2576

Cairn Clark (651) 250-2291

ECOLAB ANNOUNCES STRONG FOURTH QUARTER PERFORMANCE AND 2024 OUTLOOK

REPORTED DILUTED EPS $1.41; ADJUSTED DILUTED EPS $1.55, +22%

2024 ADJUSTED DILUTED EPS OUTLOOK: $6.10 TO $6.50, +17% TO 25%

FOURTH QUARTER HIGHLIGHTS

Reported sales $3.9 billion, +7% versus last year. Organic sales +6%, led by double-digit growth in the Institutional & Specialty segment and Pest Elimination, and solid Industrial segment growth. As expected, Healthcare & Life Sciences segment sales were stable versus last year but continued to show good sequential sales growth.
Reported operating income +48%. Organic operating income +21%, driven by continued strong pricing, volume growth and moderately lower delivered product costs.
Reported operating income margin 15.0%. Organic operating income margin 16.0%, +200 bps reflecting continued robust gross margin expansion led by value-based pricing.
Reported diluted EPS $1.41, +52%. Adjusted diluted EPS, excluding special gains and charges and discrete tax items were $1.55, +22%.
Full-year 2023 cash flow from operating activities $2.4 billion. Full-year 2023 free cash flow $1.6 billion, resulting in free cash flow conversion of 118%.

OUTLOOK

1Q 2024: Expect first quarter 2024 adjusted diluted earnings per share in the $1.27 to $1.37 range, +44% to 56% versus last year reflecting short-term benefits from lower delivered product costs.
2024: Expect full year 2024 adjusted diluted earnings per share in the $6.10 to $6.50 range, +17% to 25% versus last year.

Fourth Quarter Ended December 31

Reported

Adjusted

(unaudited)

Public Currency Rates

%  

Public Currency Rates

%  

(millions, except per share)

2023

2022

Change

2023

2022

Change

Net sales

$3,938.4

$3,671.2

7

%

$3,938.4

$3,671.2

7

%

Operating income

590.0

399.2

48

%

624.5

502.4

24

%

Net income attributable to Ecolab

405.2

264.4

53

%

444.7

363.6

22

%

Diluted earnings per share attributable to Ecolab

$1.41

$0.93

52

%

$1.55

$1.27

22

%

Organic

%  

2023

2022

Change

Net sales

$3,921.1

$3,703.6

6

%

Operating income

628.0

517.2

21

%

1


ST. PAUL, Minn., February 13, 2024

CEO Comment

Christophe Beck, Ecolab’s chairman and chief executive officer, said, “2023 was a phenomenal year for Ecolab, with our team delivering robust sales growth, significant operating margin expansion and very strong growth in adjusted diluted earnings per share. Our team won a significant amount of new business that helped to offset continued soft macro demand, launched a strong pipeline of new breakthrough technologies, drove pricing backed by strong customer value, and further improved our underlying productivity by leveraging our leading digital capabilities. All of this is the result of the work we have done over the last few years to further strengthen Ecolab’s key long-term growth drivers.

“We are confident 2024 will be another strong year for Ecolab, continuing our long-term 12-15% earnings growth trajectory that is amplified by shorter-term benefits from moderately lower delivered product costs. While macroeconomic conditions remain unpredictable, we are well positioned to drive growth through our ‘circle the customer, circle the globe’ enterprise selling model and proven value proposition, that helps customers improve their operational performance, while reducing their water and energy consumption. We expect another very strong year of operating margin expansion, building upon our success in 2023, and remain confident in our path to deliver on our 20% margin objective over the next few years to drive superior earnings growth and long-term returns for shareholders.”

Fourth Quarter 2023 Consolidated Results

Ecolab’s fourth quarter reported sales increased 7% and organic sales increased 6% when compared to the prior year.

 

Fourth quarter 2023 reported operating income increased 48% including the impact of special gains and charges, which were a net charge primarily related to restructuring costs. Organic operating income increased 21%, as robust pricing and moderately lower delivered product costs more than offset investments in the business including incentive compensation.

Reported other income increased in the fourth quarter of 2023 as modestly higher pension costs were more than offset by the comparison to last year’s $26 million settlement expense related to U.S. pension plan lump-sum payments to retirees.

2


Reported interest expense increased 1% reflecting the impact from higher average interest rates on outstanding debt.

The reported income tax rate for the fourth quarter of 2023 was 23.6% compared with the reported rate of 16.2% in the fourth quarter of 2022. Excluding special gains and charges and discrete tax items, the adjusted tax rate for the fourth quarter of 2023 was 21.3% compared with the adjusted tax rate of 18.2% in the fourth quarter of 2022. The increase in the fourth quarter tax rate was due to changes in the geographic mix of income and timing of tax planning.

Reported net income increased 53% versus the prior year. Excluding the impact of special gains and charges and discrete tax items, adjusted net income increased 22% versus the prior year.

Reported diluted earnings per share increased 52% versus the prior year. Adjusted diluted earnings per share increased 22% when compared against the fourth quarter of 2022.

Currency translation had a $0.02 favorable impact on earnings per share in the fourth quarter of 2023.

Fourth Quarter 2023 Segment Review

Global Industrial

(unaudited)

Fourth Quarter Ended December 31

Organic

(millions)

    

2023

2022

% Change

    

% Change

Fixed currency

Sales

$1,871.3

$1,808.2

3

%

3

%

Operating income

322.2

272.5

18

%

18

%

Operating income margin

17.2

%

15.1

%

Organic operating income margin

17.3

%

15.1

%

Public currency

Sales

$1,862.1

$1,779.8

5

%

Operating income

319.6

265.8

20

%

The Industrial segment includes Water, Food & Beverage, and Paper

Organic sales increased 3% as good growth in Water and Food & Beverage more than offset the expected short-term decline in Paper sales, which continues to be impacted by soft industry demand.

3


Organic operating income increased 18% as continued pricing and lower delivered product costs overcame investments in the business and softer volume.

Global Institutional & Specialty

(unaudited)

Fourth Quarter Ended December 31

Organic

(millions)

    

2023

2022

% Change

    

% Change

Fixed currency

Sales

$1,290.1

$1,139.1

13

%

12

%

Operating income

238.7

169.3

41

%

41

%

Operating income margin

18.5

%

14.9

%

Organic operating income margin

18.8

%

14.9

%

Public currency

Sales

$1,285.2

$1,127.4

14

%

Operating income

237.5

166.7

42

%

The Institutional & Specialty segment includes Institutional and Specialty

Organic sales increased 12%, with both the Institutional and Specialty divisions growing double-digits, driven by robust pricing and new business gains. Very strong organic operating income growth of 41% reflected strong pricing, good volume growth and lower delivered product costs that more than offset investments in the business including incentive compensation.

Global Healthcare & Life Sciences

(unaudited)

Fourth Quarter Ended December 31

Organic

(millions)

    

2023

2022

% Change

    

% Change

Fixed currency

Sales

$410.1

$413.1

(1)

%

(1)

%

Operating income

48.3

64.2

(25)

%

(25)

%

Operating income margin

11.8

%

15.5

%

Organic operating income margin

11.8

%

15.5

%

Public currency

Sales

$409.3

$400.2

2

%

Operating income

47.8

61.3

(22)

%

The Healthcare & Life Sciences segment includes Healthcare and Life Sciences

Sequentially, Healthcare and Life Sciences segment organic sales and operating income continued to improve. Compared to last year, organic sales were stable as continued solid growth in Healthcare

4


largely offset the expected decline in Life Sciences. Healthcare’s performance continued to improve reflecting early benefits from the separation of our North America operations into two focused businesses, infection prevention and surgical. Life Sciences’ underlying performance remained stable as new business wins and pricing were more than offset by comparisons to last year’s very strong 18% growth. Organic operating income decreased 25% versus last year as further pricing was more than offset by targeted investments in the business and higher supply chain costs.

Other

(unaudited)

Fourth Quarter Ended December 31

Organic

(millions)

    

2023

2022

% Change

    

% Change

Fixed currency

Sales

$370.1

$343.2

8

%

8

%

Operating income

68.6

57.9

18

%

18

%

Operating income margin

18.5

%

16.9

%

Organic operating income margin

18.5

%

16.9

%

Public currency

Sales

$368.2

$336.4

9

%

Operating income

67.8

56.3

20

%

The Other segment includes Pest Elimination, Textile Care and Colloidal Technologies

Organic sales increased 8%, led by double-digit growth in Pest Elimination. Organic operating income increased 18% as continued pricing and lower delivered product costs more than offset investments in the business.

Corporate

(unaudited)

Fourth Quarter Ended December 31

(millions)

    

2023

2022

Public currency

Sales

$13.6

$27.4

Corporate operating expense

Nalco and Purolite amortization

49.8

47.7

Special (gains) and charges

34.5

103.2

Other

(1.6)

-

Total Corporate operating expense

$82.7

$150.9

5


Fourth quarter of 2023 corporate segment includes:

sales of $14 million to ChampionX under the Master Cross Supply and Product Transfer agreements Ecolab entered into as part of the ChampionX separation
amortization expense of $29 million related to the Nalco merger intangible assets and $21 million related to Purolite acquisition intangible assets
special gains and charges were a net charge of $35 million, primarily related to restructuring costs

Special gains and charges for the fourth quarter of 2022 impacting operating expense were a net charge of $103 million and primarily related restructuring costs.

Business Outlook

2024

Ecolab expects full year 2024 adjusted diluted earnings per share in the $6.10 to $6.50 range, rising 17% to 25% compared with adjusted diluted earnings per share of $5.21 in 2023. This forecast assumes soft but stable macroeconomic demand and lower delivered product costs in the first half of the year as global inflation eases. Higher interest expense, pension expense and foreign currency translation are estimated to have a combined $0.05 per share unfavorable impact in 2024.

Against this backdrop, Ecolab expects sales growth, driven by new business gains and continued value-based pricing, SG&A productivity through the year, and attractive operating income margin expansion. This strong performance is expected to result in quarterly adjusted diluted earnings per share growth that progressively normalizes towards the upper-end of Ecolab’s long-term 12-15% target as favorability from lower delivered product costs is only assumed in the first half of the year.

The company currently expects quantifiable special charges in 2024 to be approximately $0.10 to $0.15 per share, principally related to restructuring charges. Other than the special gains and charges noted above, other such amounts are not currently quantifiable.  

2024 – First Quarter

Ecolab expects first quarter 2024 adjusted diluted earnings per share in the $1.27 to $1.37 range, rising 44% to 56% compared with adjusted diluted earnings per share of $0.88 a year ago.

6


The company currently expects quantifiable special charges in the first quarter of 2024 to be approximately $0.08 per share, principally related to restructuring charges. Other than the special gains and charges noted above, other such amounts are not currently quantifiable.  

About Ecolab

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $15 billion, employs more than 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets. www.ecolab.com

Ecolab will host a live webcast to review the fourth quarter earnings announcement today at 1:00 p.m. Eastern Time. The webcast, along with related materials, will be available to the public on Ecolab's website at www.ecolab.com/investor. A replay of the webcast and related materials will be available at that site.

Cautionary Statements Regarding Forward-Looking Information

This news release contains certain statements relating to future events and our intentions, beliefs, expectations and predictions for the future which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project,” “may,” “will,” “intend,” “plan,” “believe,” “target,” “forecast” (including the negative or variations thereof) or similar terminology used in connection with any discussion of future plans, actions or events generally identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding macroeconomic conditions, delivered product costs, demand, inflation, and our financial and business performance and prospects, including sales, earnings, special charges, margins, pricing, productivity and new business. These statements are based on the current expectations of management of the company. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this news release. In particular, the ultimate results of any restructuring initiative depend

7


on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness.

Additional risks and uncertainties that may affect operating results and business performance are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the impact of economic factors such as the worldwide economy, interest rates, foreign currency risk, reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar, demand uncertainty, supply chain challenges and inflation; the vitality of the markets we serve; exposure to global economic, political and legal risks related to our international operations, including geopolitical instability and the escalation of armed conflicts; our ability to successfully execute organizational change and management transitions; information technology infrastructure failures or breaches in data security; difficulty in procuring raw materials or fluctuations in raw material costs; the occurrence of severe public health outbreaks not limited to COVID-19; our ability to acquire complementary businesses and to effectively integrate such businesses; our ability to execute key business initiatives; our ability to successfully compete with respect to value, innovation and customer support; pressure on operations from consolidation of customers or vendors; restraints on pricing flexibility due to contractual obligations and our ability to meet our contractual commitments; the costs and effects of complying with laws and regulations, including those relating to the environment, climate change standards, and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; potential chemical spill or release; our commitments, goals, targets, objectives and initiatives related to sustainability; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with covenants that apply to our indebtedness; potential losses arising from the impairment of goodwill or other assets; and other uncertainties or risks reported from time to time in our reports to the SEC. In light of these risks, uncertainties, assumptions

8


and factors, the forward-looking events discussed in this news release may not occur. We caution that undue reliance should not be placed on forward-looking statements, which speak only as of the date made. Ecolab does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations, except as required by law.

Non-GAAP Financial Information

This news release and certain of the accompanying tables include financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (“GAAP”).

These non-GAAP financial measures include:

fixed currency sales

organic sales, formerly known as acquisition adjusted fixed currency sales

adjusted cost of sales

adjusted gross profit

adjusted gross margin

fixed currency operating income

adjusted operating income

adjusted fixed currency operating income

adjusted fixed currency operating income margin

organic operating income, formerly known as acquisition adjusted fixed currency operating income

organic operating income margin, formerly known as acquisition adjusted fixed currency operating income margin

adjusted tax rate

adjusted net income attributable to Ecolab

adjusted diluted earnings per share

free cash flow

free cash flow conversion

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and

9


that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for adjusted cost of sales, adjusted gross margin, adjusted gross profit and adjusted operating income exclude the impact of special (gains) and charges and our non-GAAP financial measures for adjusted tax rate, adjusted net income attributable to Ecolab and adjusted diluted earnings per share further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this release are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2023. We also provide our segment results based on public currency rates for informational purposes.

Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to the Company’s reportable segments.

Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude the impact of special (gains) and charges, the results of our acquired businesses from the first twelve months post acquisition and the results of divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months and for a small set of products with limited suppliers over the next few years. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

10


We define free cash flow as net cash provided by operating activities less cash outlays for capital expenditures and free cash flow conversion as free cash flow divided by net income including noncontrolling interest. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. These measures should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. We believe these measures are meaningful to investors as they function as a useful measure of performance and we use them as an indication of the strength of the Company and its ability to generate cash.

These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in this news release. Reconciliations of our non-GAAP measures are included in the following "Supplemental Non-GAAP Reconciliations" and “Supplemental Diluted Earnings per Share Information” tables included in this news release.

We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this news release) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information.

###

(ECL-E)

11


ECOLAB INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

Fourth Quarter Ended

Twelve Months Ended

 

December 31

%  

December 31

%  

(millions, except per share)

2023

   

2022

Change

   

2023

   

2022

   

Change

Product and equipment sales

$3,164.8

$2,972.3

$12,316.8

$11,446.2

Service and lease sales

773.6

698.9

3,003.4

2,741.6

Net sales

3,938.4

3,671.2

7

%

15,320.2

14,187.8

8

%

Product and equipment cost of sales

1,827.5

1,841.1

7,389.2

7,212.8

Service and lease cost of sales

456.9

413.8

1,765.7

1,618.2

Cost of sales (1)

2,284.4

2,254.9

1

%

9,154.9

8,831.0

4

%

Selling, general and administrative expenses

1,034.8

922.1

12

%

4,061.6

3,653.8

11

%

Special (gains) and charges (1)

29.2

95.0

111.4

140.5

Operating income

590.0

399.2

48

%

1,992.3

1,562.5

28

%

Other (income) expense (1)

(17.9)

8.1

(321)

%

(59.9)

(24.5)

144

%

Interest expense, net

70.4

69.5

1

%

296.7

243.6

22

%

Income before income taxes

537.5

321.6

67

%

1,755.5

1,343.4

31

%

Provision for income taxes

126.7

52.1

143

%

362.5

234.5

55

%

Net income including noncontrolling interest

410.8

269.5

52

%

1,393.0

1,108.9

26

%

Net income attributable to noncontrolling interest

5.6

5.1

20.7

17.2

Net income attributable to Ecolab

$405.2

$264.4

53

%

$1,372.3

$1,091.7

26

%

Earnings attributable to Ecolab per common share

Basic

$1.42

$0.93

53

%

$4.82

$3.83

26

%

Diluted

$1.41

$0.93

52

%

$4.79

$3.81

26

%

Weighted-average common shares outstanding

Basic

285.3

284.6

0

%

285.0

285.2

0

%

Diluted

287.1

285.8

0

%

286.5

286.6

0

%

(1) Cost of sales, Special (gains) and charges and Other (income) expense in the Consolidated Statement of Income above include the following:

Fourth Quarter Ended

Twelve Months Ended

 

December 31

December 31

(millions)

2023

2022

2023

2022

Cost of sales

Restructuring activities

$5.3

$15.9

$22.5

$21.4

Acquisition and integration activities

-

(7.7)

-

25.0

COVID-19 activities, net

-

-

-

16.3

Russia/Ukraine activities

-

-

-

7.2

Subtotal (a)

5.3

8.2

22.5

69.9

Special (gains) and charges

Restructuring activities

16.9

85.0

63.2

85.8

Acquisition and integration activities

4.6

(0.5)

16.1

14.5

COVID-19 activities, net

-

3.1

-

10.2

Russia/Ukraine activities

0.3

-

1.4

5.9

Other

7.4

7.4

30.7

24.1

Subtotal

29.2

95.0

111.4

140.5

Other (income) expense

Pension Settlements/Curtailments

-

25.8

-

50.6

Total special (gains) and charges

$34.5

$129.0

$133.9

$261.0

(a) Special charges of $3.5 million and $6.2 million in the fourth quarter of 2023 and 2022, respectively, and $14.5 million and $65.0 million for the twelve months of 2023 and 2022, respectively, were recorded in product and equipment cost of sales. Special charges of $1.8 million and $2.0 million in the fourth quarter of 2023 and 2022, respectively, and $8.0 million and $4.9 million for the twelve months of 2023 and 2022, respectively, were recorded in service and lease cost of sales.

12


ECOLAB INC.

REPORTABLE SEGMENT INFORMATION

(unaudited)

Fourth Quarter Ended December 31

Fixed Currency Rates

Public Currency Rates

%

%

(millions)

2023

    

2022

    

Change

    

2023

    

2022

    

Change

Net Sales

Global Industrial

$1,871.3

$1,808.2

3

%

$1,862.1

$1,779.8

5

%

Global Institutional & Specialty

1,290.1

1,139.1

13

%

1,285.2

1,127.4

14

%

Global Healthcare & Life Sciences

410.1

413.1

(1)

%

409.3

400.2

2

%

Other

370.1

343.2

8

%

368.2

336.4

9

%

Corporate

13.8

27.6

(50)

%

13.6

27.4

(50)

%

Subtotal at fixed currency rates

3,955.4

3,731.2

6

%

3,938.4

3,671.2

7

%

Currency impact

(17.0)

(60.0)

*

-

-

*

Consolidated reported GAAP net sales

$3,938.4

$3,671.2

7

%

$3,938.4

$3,671.2

7

%

Operating Income (loss)

Global Industrial

$322.2

$272.5

18

%

$319.6

$265.8

20

%

Global Institutional & Specialty

238.7

169.3

41

%

237.5

166.7

42

%

Global Healthcare & Life Sciences

48.3

64.2

(25)

%

47.8

61.3

(22)

%

Other

68.6

57.9

18

%

67.8

56.3

20

%

Corporate

(83.3)

(151.4)

*

(82.7)

(150.9)

*

Subtotal at fixed currency rates

594.5

412.5

44

%

590.0

399.2

48

%

Currency impact

(4.5)

(13.3)

*

-

-

*

Consolidated reported GAAP operating income

$590.0

$399.2

48

%

$590.0

$399.2

48

%

Year Ended December 31

Fixed Currency Rates

Public Currency Rates

%

%

(millions)

2023

    

2022

    

Change

    

2023

    

2022

    

Change

Net Sales

Global Industrial

$7,193.1

$6,736.3

7

%

$7,221.8

$6,805.0

6

%

Global Institutional & Specialty

4,994.0

4,414.3

13

%

4,999.2

4,432.1

13

%

Global Healthcare & Life Sciences

1,576.9

1,505.8

5

%

1,586.0

1,510.5

5

%

Other

1,442.3

1,313.3

10

%

1,444.2

1,316.4

10

%

Corporate

69.1

123.7

(44)

%

69.0

123.8

(44)

%

Subtotal at fixed currency rates

15,275.4

14,093.4

8

%

15,320.2

14,187.8

8

%

Currency impact

44.8

94.4

*

-

-

*

Consolidated reported GAAP net sales

$15,320.2

$14,187.8

8

%

$15,320.2

$14,187.8

8

%

Operating Income

Global Industrial

$1,080.7

$935.8

15

%

$1,084.7

$950.0

14

%

Global Institutional & Specialty

823.0

621.7

32

%

823.4

624.3

32

%

Global Healthcare & Life Sciences

160.0

193.3

(17)

%

161.5

193.5

(17)

%

Other

255.0

209.9

21

%

254.4

209.5

21

%

Corporate

(331.7)

(414.4)

*

(331.7)

(414.8)

*

Subtotal at fixed currency rates

1,987.0

1,546.3

29

%

1,992.3

1,562.5

28

%

Currency impact

5.3

16.2

*

-

-

*

Consolidated reported GAAP operating income

$1,992.3

$1,562.5

28

%

$1,992.3

$1,562.5

28

%

* Not meaningful.

As shown in the “Fixed Currency Rates” tables above, we evaluate the performance of our international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Amounts shown in the “Public Currency Rates” tables above reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and are provided for informational purposes. The difference between the fixed currency exchange rates and the public currency exchange rates is reported as “Currency impact” in the “Fixed Currency Rates” tables above.

The Corporate segment includes amortization from the Nalco and Purolite transactions intangible assets. The Corporate segment also includes special (gains) and charges reported on the Consolidated Statement of Income.

13


ECOLAB INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

December 31

December 31

(millions)

2023

2022

Assets

Current assets

Cash and cash equivalents

$919.5

$598.6

Accounts receivable, net

2,834.2

2,698.1

Inventories

1,497.2

1,792.8

Other current assets

393.2

404.7

Total current assets

5,644.1

5,494.2

Property, plant and equipment, net

3,474.6

3,293.4

Goodwill

8,148.2

8,012.7

Other intangible assets, net

3,493.5

3,680.7

Operating lease assets

553.5

448.2

Other assets

532.7

535.1

Total assets

$21,846.6

$21,464.3

Liabilities and Equity

Current liabilities

Short-term debt

$630.4

$505.1

Accounts payable

1,566.3

1,728.2

Compensation and benefits

655.5

493.6

Income taxes

158.7

197.6

Other current liabilities

1,334.9

1,285.9

Total current liabilities

4,345.8

4,210.4

Long-term debt

7,551.4

8,075.3

Pension and postretirement benefits

651.7

670.3

Deferred income taxes

418.2

505.6

Operating lease liabilities

425.5

337.8

Other liabilities

381.8

406.3

Total liabilities

13,774.4

14,205.7

Equity

Common stock

365.7

364.7

Additional paid-in capital

6,766.7

6,580.2

Retained earnings

10,075.4

9,318.8

Accumulated other comprehensive loss

(1,850.4)

(1,726.6)

Treasury stock

(7,312.7)

(7,301.0)

Total Ecolab shareholders’ equity

8,044.7

7,236.1

Noncontrolling interest

27.5

22.5

Total equity

8,072.2

7,258.6

Total liabilities and equity

$21,846.6

$21,464.3

14


ECOLAB INC.

SUPPLEMENTAL NON-GAAP RECONCILIATIONS

(unaudited)

    

Fourth Quarter Ended

    

Twelve Months Ended

 

December 31

December 31

(millions, except percent and per share)

2023

   

2022

2023

   

2022

Net sales

Reported GAAP net sales

$3,938.4

$3,671.2

$15,320.2

$14,187.8

Effect of foreign currency translation

17.0

60.0

(44.8)

(94.4)

Non-GAAP fixed currency sales

3,955.4

3,731.2

15,275.4

14,093.4

Effect of acquisitions and divestitures

(34.3)

(27.6)

(113.4)

(123.7)

Non-GAAP organic sales

$3,921.1

$3,703.6

$15,162.0

$13,969.7

Cost of sales

Reported GAAP cost of sales

$2,284.4

$2,254.9

$9,154.9

$8,831.0

Special (gains) and charges

5.3

8.2

22.5

69.9

Non-GAAP adjusted cost of sales

$2,279.1

$2,246.7

$9,132.4

$8,761.1

Gross profit

Reported GAAP gross profit

$1,654.0

$1,416.3

$6,165.3

$5,356.8

Special (gains) and charges

5.3

8.2

22.5

69.9

Non-GAAP adjusted gross profit

$1,659.3

$1,424.5

$6,187.8

$5,426.7

Gross margin

Reported GAAP gross margin

42.0

%

38.6

%

40.2

%

37.8

%

Non-GAAP adjusted gross margin

42.1

%

38.8

%

40.4

%

38.2

%

Operating income

Reported GAAP operating income

$590.0

$399.2

$1,992.3

$1,562.5

Special (gains) and charges at public currency rates

34.5

103.2

133.9

210.4

Non-GAAP adjusted operating income

624.5

502.4

2,126.2

1,772.9

Effect of foreign currency translation

4.6

14.8

(5.8)

(13.1)

Non-GAAP adjusted fixed currency operating income

629.1

517.2

2,120.4

1,759.8

Effect of acquisitions and divestitures

(1.1)

-

(2.9)

(0.4)

Non-GAAP organic operating income

$628.0

$517.2

$2,117.5

$1,759.4

Operating income margin

Reported GAAP operating income margin

15.0

%

10.9

%

13.0

%

11.0

%

Non-GAAP adjusted fixed currency operating income margin

15.9

%

13.9

%

13.9

%

12.5

%

Non-GAAP organic operating income margin

16.0

%

14.0

%

14.0

%

12.6

%

15


ECOLAB INC.

SUPPLEMENTAL NON-GAAP RECONCILIATIONS

(unaudited)

    

Fourth Quarter Ended

    

Twelve Months Ended

December 31

December 31

(millions, except percent and per share)

2023

   

2022

2023

   

2022

Other (income) expense

Reported GAAP other (income) expense

($17.9)

$8.1

($59.9)

($24.5)

Special (gains) and charges

-

25.8

-

50.6

Non-GAAP adjusted other (income) expense

($17.9)

($17.7)

($59.9)

($75.1)

Net Income attributable to Ecolab

Reported GAAP net income attributable to Ecolab

$405.2

$264.4

$1,372.3

$1,091.7

Special (gains) and charges, after tax

30.6

101.5

109.2

207.3

Discrete tax net expense (benefit)

8.9

(2.3)

11.2

(11.8)

Non-GAAP adjusted net income attributable to Ecolab

$444.7

$363.6

$1,492.7

$1,287.2

Diluted EPS attributable to Ecolab

Reported GAAP diluted EPS

$1.41

$0.93

$4.79

$3.81

Special (gains) and charges, after tax

0.11

0.35

0.38

0.72

Discrete tax net expense (benefit)

0.03

(0.01)

0.04

(0.04)

Non-GAAP adjusted diluted EPS

$1.55

$1.27

$5.21

$4.49

Provision for Income Taxes

Reported GAAP tax rate

23.6

%

16.2

%

20.6

%

17.5

%

Special gains and charges

(0.8)

1.5

(0.1)

0.5

Discrete tax items

(1.5)

0.5

(0.6)

0.7

Non-GAAP adjusted tax rate

21.3

%

18.2

%

19.9

%

18.7

%

16


ECOLAB INC.

SUPPLEMENTAL NON-GAAP RECONCILIATIONS

(unaudited)

Fourth Quarter Ended December 31

2023

2022

(millions)

Fixed Currency

Impact of Acquisitions and Divestitures

Organic

Fixed Currency

Impact of Acquisitions and Divestitures

Organic

Net Sales

Global Industrial

$1,871.3

($4.5)

$1,866.8

$1,808.2

$ -

$1,808.2

Global Institutional & Specialty

1,290.1

(16.0)

1,274.1

1,139.1

-

1,139.1

Global Healthcare & Life Sciences

410.1

-

410.1

413.1

-

413.1

Other

370.1

-

370.1

343.2

-

343.2

Corporate

13.8

(13.8)

-

27.6

(27.6)

-

Subtotal at fixed currency rates

3,955.4

(34.3)

3,921.1

3,731.2

(27.6)

3,703.6

Currency impact

(17.0)

(60.0)

Consolidated reported GAAP net sales

$3,938.4

$3,671.2

Operating Income (loss)

Global Industrial

$322.2

$0.2

$322.4

$272.5

$ -

$272.5

Global Institutional & Specialty

238.7

0.3

239.0

169.3

-

169.3

Global Healthcare & Life Sciences

48.3

-

48.3

64.2

-

64.2

Other

68.6

-

68.6

57.9

-

57.9

Corporate

(48.7)

(1.6)

(50.3)

(46.7)

-

(46.7)

Subtotal at fixed currency rates

629.1

(1.1)

628.0

517.2

-

517.2

Special (gains) and charges at fixed currency rates

34.6

104.7

Reported OI at fixed currency rates

594.5

412.5

Currency impact

(4.5)

(13.3)

Consolidated reported GAAP operating income

$590.0

$399.2

Year Ended December 31

2023

2022

(millions)

Fixed Currency

Impact of Acquisitions and Divestitures

Organic

Fixed Currency

Impact of Acquisitions and Divestitures

Organic

Net Sales

Global Industrial

$7,193.1

($4.5)

$7,188.6

$6,736.3

$ -

$6,736.3

Global Institutional & Specialty

4,994.0

(39.8)

4,954.2

4,414.3

-

4,414.3

Global Healthcare & Life Sciences

1,576.9

-

1,576.9

1,505.8

-

1,505.8

Other

1,442.3

-

1,442.3

1,313.3

-

1,313.3

Corporate

69.1

(69.1)

-

123.7

(123.7)

-

Subtotal at fixed currency rates

15,275.4

(113.4)

15,162.0

14,093.4

(123.7)

13,969.7

Currency impact

44.8

94.4

Consolidated reported GAAP net sales

$15,320.2

$14,187.8

Operating Income (loss)

Global Industrial

$1,080.7

$0.2

$1,080.9

$935.8

$ -

$935.8

Global Institutional & Specialty

823.0

(0.5)

822.5

621.7

-

621.7

Global Healthcare & Life Sciences

160.0

-

160.0

193.3

-

193.3

Other

255.0

-

255.0

209.9

-

209.9

Corporate

(198.3)

(2.6)

(200.9)

(200.9)

(0.4)

(201.3)

Subtotal at fixed currency rates

2,120.4

(2.9)

2,117.5

1,759.8

(0.4)

1,759.4

Special (gains) and charges at fixed currency rates

133.4

213.5

Reported OI at fixed currency rates

1,987.0

1,546.3

Currency impact

5.3

16.2

Consolidated reported GAAP operating income

$1,992.3

$1,562.5

17


ECOLAB INC.

SUPPLEMENTAL NON-GAAP RECONCILIATIONS

(unaudited)

Selected Cash Flow items

Fourth Quarter Ended

Twelve Months Ended

December 31

December 31

(millions)

2023

2022

2023

2022

Cash provided by operating activities

$852.5

$859.2

$2,411.8

$1,788.4

Less: Capital expenditures

(262.6)

(202.8)

(774.8)

(712.8)

Free cash flow

$589.9

$656.4

$1,637.0

$1,075.6

Net income (including noncontrolling interest)

410.8

269.5

1,393.0

1,108.9

Cash flow conversion

208%

319%

173%

161%

Free cash flow conversion

144%

244%

118%

97%

18


ECOLAB INC.

SUPPLEMENTAL DILUTED EARNINGS PER SHARE INFORMATION

(unaudited)

The table below provides a reconciliation of diluted earnings per share, as reported, to the non-GAAP measure of adjusted diluted earnings per share.

    

First

    

Second

    

Six

    

Third

    

Nine

    

Fourth

    

    

Quarter

Quarter

Months

Quarter

Months

Quarter

Year

Ended

Ended

Ended

Ended

Ended

Ended

Ended

Mar. 31

June 30

June 30

Sept. 30

Sept. 30

Dec. 31

Dec. 31

2022

2022

2022

2022

2022

2022

2022

Diluted earnings per share, as reported (U.S. GAAP)

$0.60

$1.08

$1.67

$1.21

$2.88

$0.93

$3.81

Adjustments:

Special (gains) and charges (1)

0.22

0.01

0.23

0.14

0.37

0.35

0.72

Discrete tax expense (benefits) (2)

0.00

0.01

0.02

(0.05)

(0.03)

(0.01)

(0.04)

Adjusted diluted earnings per share (Non-GAAP)

$0.82

$1.10

$1.92

$1.30

$3.22

$1.27

$4.49

    

First

    

Second

    

Six

    

Third

    

Nine

    

Fourth

    

    

 

Quarter

Quarter

Months

Quarter

Months

Quarter

Year

 

Ended

Ended

Ended

Ended

Ended

Ended

Ended

 

Mar. 31

June 30

June 30

Sept. 30

Sept. 30

Dec. 31

Dec. 31

 

2023

2023

2023

2023

2023

2023

2023

 

Diluted earnings per share, as reported (U.S. GAAP)

$0.82

$1.15

$1.97

$1.41

$3.38

$1.41

$4.79

Adjustments:

Special (gains) and charges (3)

0.07

0.08

0.15

0.12

0.27

0.11

0.38

Discrete tax expense (benefits) (4)

(0.01)

0.01

0.00

0.01

0.01

0.03

0.04

Adjusted diluted earnings per share (Non-GAAP)

$0.88

$1.24

$2.12

$1.54

$3.66

$1.55

$5.21

Per share amounts do not necessarily sum due to changes in shares outstanding and rounding.

(1) Special (gains) and charges for 2022 includes charges of $63.6 million, $2.6 million, $39.6 million and $101.5 million, net of tax, in the first, second, third and fourth quarters, respectively. These charges were primarily related to acquisition and integration charges, reserves related to our operations in Russia, COVID-19 related inventory write downs and employee-related costs, restructuring charges, litigation and other charges and pension settlements.

(2) Discrete tax expenses (benefits) for 2022 includes $1.0 million, $3.7 million, ($14.2) million and ($2.3) million in the first, second, third and fourth quarters, respectively. These expenses (benefits) are primarily associated with stock compensation excess tax benefits and other discrete tax benefits.

(3) Special (gains) and charges for 2023 includes charges of $21.1 million, $23.3 million, $34.2 million and $30.6 million, net of tax, in the first, second, third and fourth quarters, respectively. These charges were primarily related to restructuring charges, acquisition and integration charges and litigation and other charges.

(4) Discrete tax (benefits) for 2023 includes ($4.0) million, $2.8 million, $3.5 million and $8.9 million in the first, second, third and fourth quarters, respectively. These expenses (benefits) are primarily associated with stock compensation excess tax benefits and other discrete tax benefits.

19


Exhibit 99.2

GRAPHIC

1 ECOLAB Fourth Quarter 2023 Supplemental

GRAPHIC

Cautionary statement Forward-Looking Information This communication contains forward looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding macroeconomic conditions, delivered product costs, demand, inflation, and our financial and business performance and prospects, including sales, earnings, margins, pricing, productivity, new business, interest expense, pension expense and foreign currency translation. These statements are based on the current expectations of management. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. In particular, the ultimate results of any restructuring initiative depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. Additional risks and uncertainties are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (“SEC”), and include the impact of economic factors such as the worldwide economy, interest rates, foreign currency risk, reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar, demand uncertainty, supply chain challenges and inflation; the vitality of the markets we serve; exposure to global economic, political and legal risks related to our international operations, including geopolitical instability and the escalation of armed conflicts; our ability to successfully execute organizational change and management transitions; information technology infrastructure failures or breaches in data security; difficulty in procuring raw materials or fluctuations in raw material costs; the occurrence of severe public health outbreaks not limited to COVID-19; our ability to acquire complementary businesses and to effectively integrate such businesses; and other uncertainties or risks reported from time to time in our reports to the SEC. In light of these risks, uncertainties and factors, the forward-looking events discussed in this communication may not occur. We caution that undue reliance should not be placed on forward-looking statements, which speak only as of the date made. Ecolab does not undertake, and expressly disclaims, any duty to update any forward-looking statement, except as required by law. Non-GAAP Financial Information This communication includes Company information that does not conform to generally accepted accounting principles (GAAP). Management believes that a presentation of this information is meaningful to investors because it provides insight with respect to ongoing operating results of the Company and allows investors to better evaluate the financial results of the Company. These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. Reconciliations of our non-GAAP measures included within this presentation are included in the “Non-GAAP Financial Measures” section of this presentation.

GRAPHIC

Very strong 4Q performance and 2024 outlook 3 Continued robust sales growth Strong double-digit OI growth with significant OI margin expansion Reported EPS $1.41; Adjusted EPS $1.55, +22% Confident 2024 will be another strong year for Ecolab ▪ Reported sales +7%, organic sales +6% ▪ Volume trends improved as good new business gains offset soft macro end-market demand ▪ Reported OI +48%, organic OI +21% ▪ Reported OI margin 15.0%. Organic OI margin 16.0%, +200 bps reflecting robust gross margin expansion led by value-based pricing ▪ Increased confidence to reach 20% organic OI margin within the next few years ▪ Strong performance driven by continued robust pricing, volume growth, and moderately lower delivered product costs ▪ 2024 outlook: expect adjusted diluted EPS in the $6.10 to $6.50 range, +17% to +25% versus last year. This outlook assumes soft but stable macroeconomic demand and lower delivered product costs in the first half of the year ▪ 1Q outlook: expect adjusted diluted EPS in the $1.27 to $1.37 range, +44% to +56% versus last year ▪ Remain committed to our long-term financial objectives

GRAPHIC

4Q overview ▪ Strong growth with reported sales +7% and organic sales +6% o Pricing +5%, reflected further value-based pricing on top of last year’s strong pricing o Volumes improved to +1% as new business overcame soft macroeconomic demand ▪ Strong organic growth led by the Institutional & Specialty segment o Industrial +3%, led by good growth in Water and Food & Beverage o Institutional & Specialty +12%, with both divisions growing double-digits o Healthcare & Life Sciences -1%, continued to show good sequential growth o Other +8%, driven by double-digit Pest Elimination sales growth ▪ Reported diluted EPS $1.41 ▪ Adjusted diluted EPS $1.55, +22% o Strong growth reflected continued robust pricing, volume growth, and moderately lower delivered product costs Sales EPS 4

GRAPHIC

Expect strong 1Q and 2024 performance 1Q 2024 ▪ Ecolab expects first quarter 2024 adjusted diluted earnings per share in the $1.27 to $1.37 range, rising 44% to 56% compared with adjusted diluted earnings per share of $0.88 a year ago. ▪ Ecolab expects full year 2024 adjusted diluted earnings per share in the $6.10 to $6.50 range, rising 17% to 25% compared with adjusted diluted earnings per share of $5.21 in 2023. This forecast assumes soft but stable macroeconomic demand and lower delivered product costs in the first half of the year as global inflation eases. Higher interest expense, pension expense and foreign currency translation are estimated to have a combined $0.05 per share unfavorable impact in 2024. ▪ Against this backdrop, Ecolab expects sales growth, driven by new business gains and continued value-based pricing, SG&A productivity through the year, and attractive operating income margin expansion. This strong performance is expected to result in quarterly adjusted diluted earnings per share growth that progressively normalizes towards the upper-end of Ecolab’s long-term 12-15% target as favorability from lower delivered product costs is only assumed in the first half of the year. 5

GRAPHIC

4Q 2023 sales growth detail Amounts in the tables above may reflect rounding. Organic excludes sales to ChampionX post-separation. 6 Fixed Rate Organic % Change % Change Global Industrial Consolidated Water 6% 5% Volume 1% Food & Beverage 4% 4% Pricing 5% Paper -5% -5% Subtotal 6% Total Global Industrial 3% 3% Acq./Div. 0% Fixed currency growth 6% Global Institutional & Specialty Currency impact 1% Institutional 12% 12% Total 7% Specialty 16% 11% Total Global Institutional & Specialty 13% 12% Global Healthcare & Life Sciences Healthcare 4% 4% Life Sciences -8% -8% Total Global Healthcare & Life Sciences -1% -1% Other Pest Elimination 11% 11% Textile Care 1% 1% Colloidal Technologies -3% -3% Total Other 8% 8% Total 6% 6% % Change

GRAPHIC

▪ Good sales growth driven by robust pricing and new business wins, which overcame comparisons to last year’s very strong 13% growth. o Light Water: good sales growth led by continued very strong performance across data centers and microelectronics, and good growth in institutional. o Heavy Water: good growth reflecting strong gains in primary metals and solid growth in chemicals. o Downstream: strong sales growth driven by innovative water treatment programs that help our customers improve the sustainability of their operations. o Mining: good growth reflecting continued benefits from our strategic shift toward water management and productivity enhancing programs for high-value metals and fertilizers, more than offset comparisons to last year’s very strong double-digit growth. ▪ The impact of increasing water demand, its growing quality and availability issues, and the resulting rising costs continue to be a critical issue for our customers, and one that Ecolab is uniquely positioned to help them solve. Our innovative chemistry solutions, digital technologies, and service expertise help our customers significantly reduce water consumption and meet their sustainability objectives. 7 Global Industrial Segment Sales +5% Water Sales +4% Food & Beverage All sales figures are organic unless otherwise noted Q1: Expect good sales growth led by new business wins and pricing which offsets comparisons to last year’s very strong 14% growth. Q1: Anticipate solid sales growth as continued pricing and new business wins more than offset comparisons to last year’s very strong 14% growth. ▪ Solid sales growth driven by continued pricing and improved new business which overcame comparisons to last year’s very strong 17% growth. ▪ Growth was led by strong performance in dairy and solid growth in food, beverage & brewery, and animal health. ▪ Regionally, sales grew double-digits in Latin America. North America, Asia Pacific, and Europe delivered solid growth. ▪ We continue to benefit from our enterprise selling approach to customers, where we combine our industry-leading cleaning and sanitizing and water treatment capabilities to deliver significant customer value though improved product quality, food safety, water efficiency, and lower operating costs.

GRAPHIC

8 Sales -5% Paper Global Industrial Segment All sales figures are organic unless otherwise noted Q1: Expect modestly lower sales as pricing and new business wins are more than offset by soft customer production rates. ▪ As expected, moderately lower sales reflected new business wins that were more than offset by soft customer production rates and comparisons to last year’s strong 13% growth. ▪ Sales declined across graphics, board & packaging, and tissue & towel. ▪ Regionally, Latin America delivered strong growth and Asia Pacific grew modestly, but Europe and North America declined.

GRAPHIC

9 Global Institutional and Specialty Segment Sales +12% Institutional Sales +11% Specialty All sales figures are organic unless otherwise noted Q1: Expect robust sales driven by both pricing and new business wins. ▪ Strong sales growth, driven by robust pricing and new business wins. We continue to outperform rather stable end-market trends, benefiting from our innovative products and service expertise that help customers reduce costs and optimize their labor. o North America: double-digit sales growth driven by strong pricing and further new business wins. o Europe: solid growth driven by strong pricing and new business wins. o Latin America: strong growth benefiting from robust pricing. o Asia Pacific: double-digit growth, led by strong performance in China. ▪ We remain focused on capitalizing on our attractive growth opportunities, maximizing service effectiveness, and leveraging investments in digital technology to further improve productivity. We expect these enhancements, along with our innovative chemistry and digital programs which save customers time and money, will support further strong new business gains across both new and existing customers. Q1: Expect strong sales growth benefitting new business wins and further pricing. ▪ Continued robust sales growth driven by strong growth in quick service and good gains in food retail. o Quick Service: very strong sales growth driven by strong new business momentum and continued robust pricing. Strong new business wins continue to benefit from our ongoing product and program innovation that delivers leading food safety outcomes, labor optimization and lower total operating costs. o Food Retail: continued good sales growth reflected strong pricing and improved new business wins. As a trusted global partner for food retailers, we continue to expand our competitive differentiation by helping customers improve their customer experience, protect their brands, and optimize their operations.

GRAPHIC

10 Global Healthcare & Life Sciences Segment Sales +4% Healthcare Sales -8% Life Sciences All sales figures are organic unless otherwise noted Q1: Expect stable sales reflecting comparisons to strong pricing last year. ▪ Healthcare delivered solid sales growth, reflecting good pricing and improved new business gains across both North America and Europe. ▪ We continue to make good progress in the transformation of our healthcare business, as we leverage the early benefits of separating our North America operations into two focused divisions: infection prevention and surgical. This separation is yielding increased focus and growth by expanding our customer reach while also further improving our productivity, in both businesses. ▪ Our new business efforts are focused on attractive long-term growth opportunities in infection prevention and instrument reprocessing areas, while also leveraging the recovery in surgical. Our leading product lines, ongoing innovation, and digital technologies make us uniquely positioned to help improve patient outcomes while also increasing operational efficiencies for our customers. ▪ Sequentially, Life Science sales showed good growth. As expected, sales compared to last year were lower reflecting the comparisons to last year’s very strong 18% growth. Underlying performance remained stable as new business wins and pricing offset continued soft near-term industry demand. ▪ The long-term growth opportunities for the Life Sciences industry are very attractive. We continue to invest and innovate to further expand our global capabilities and technical expertise across environmental hygiene and purification technologies to capitalize on this long-term growth opportunity. Q1: Expect stable sales as new business wins and further pricing are offset by continued soft near-term industry demand.

GRAPHIC

11 Other Segments Sales +11% Pest Elimination All sales figures are organic unless otherwise noted ▪ Strong sales growth led by double-digit gains in food & beverage, restaurants, and food retail. o Growth benefited from robust new business wins and continued pricing, driven by our high service levels, innovation, and circle the customer enterprise selling strategy. ▪ Regionally, North America delivered double-digit growth, while Latin America, Europe, and China showed strong growth. Q1: Expect continued strong growth, benefiting from new customer wins as we leverage our ongoing innovation and enhanced digital offerings to further extend our competitive advantages.

GRAPHIC

Segment operating income performance ▪ Organic operating income increased 18% as continued pricing and lower delivered product costs overcame investments in the business and softer volume. ▪ Organic operating income margin expanded 220 bps versus last year. ▪ Organic operating income increased 41% as strong pricing, good volume growth and lower delivered product costs more than offset investments in the business including incentive compensation. ▪ Organic operating income margin expanded 390 bps versus last year. ▪ Organic operating income decreased 25% as further pricing was more than offset by targeted investments in the business and higher supply chain costs. ▪ Sequentially, organic operating income continued to improve. ▪ Organic operating income increased 18% as continued pricing and lower delivered product costs more than offset investments in the business. ▪ Organic operating income margin expanded 160 bps versus last year. ($ millions – fixed currency, unaudited) 12 Global Industrial 4Q 2023 4Q 2022 Change Operating income $322.2 $272.5 18% Operating income margin 17.2% 15.1% 210 bps Organic operating income $322.4 $272.5 18% Organic operating income margin 17.3% 15.1% 220 bps Global Institutional & Specialty 4Q 2023 4Q 2022 Change Operating income $238.7 $169.3 41% Operating income margin 18.5% 14.9% 360 bps Organic operating income $239.0 $169.3 41% Organic operating income margin 18.8% 14.9% 390 bps Global Healthcare & Life Sciences 4Q 2023 4Q 2022 Change Operating income $48.3 $64.2 (25%) Operating income margin 11.8% 15.5% -370 bps Organic operating income $48.3 $64.2 (25%) Organic operating income margin 11.8% 15.5% -370 bps Other Segment 4Q 2023 4Q 2022 Change Operating income $68.6 $57.9 18% Operating income margin 18.5% 16.9% 160 bps Organic operating income $68.6 $57.9 18% Organic operating income margin 18.5% 16.9% 160 bps

GRAPHIC

Consolidated margin performance ▪ Gross margin expanded significantly, reflecting strong pricing and moderately lower delivered product costs. ▪ Sales leverage and cost savings were offset by investments in the business including incentive compensation. ▪ Operating margin expanded as robust pricing and moderately lower delivered product costs more than offset investments in the business including incentive compensation. Gross Margin SG&A Operating Margin 13 $ millions, unaudited 4Q 2023 4Q 2022 Change Gross profit $1,654.0 $1,416.3 17% Gross margin 42.0% 38.6% 340 bps Adjusted gross profit $1,659.3 $1,424.5 16% Adjusted gross margin 42.1% 38.8% 330 bps SG&A $1,034.8 $922.1 12% % of Sales 26.3% 25.1% 120 bps Reported operating income $590.0 $399.2 48% Reported operating income margin 15.0% 10.9% 410 bps Adj. fixed currency operating income $629.1 $517.2 22% Adj. fixed currency operating income margin 15.9% 13.9% 200 bps Organic operating income $628.0 $517.2 21% Organic operating income margin 16.0% 14.0% 200 bps

GRAPHIC

4Q 2023 balance sheet / cash flow * EBITDA and Adjusted EBITDA are non-GAAP measures. EBITDA is defined as the sum of net income including non-controlling interest, provision for income taxes, net interest expense, depreciation and amortization, and adjusted EBITDA further adds special (gains) and charges impacting EBITDA. The inputs to EBITDA reflect the trailing twelve months of activity for the period presented. See “Non-GAAP Financial Measures” section of this presentation for corresponding reconciliations. 14 Summary Balance Sheet (millions, unaudited) 2023 2022 (millions, unaudited) 2023 2022 Cash and cash eq. $919.5 $598.6 Short-term debt $630.4 $505.1 Accounts receivable, net 2,834.2 2,698.1 Accounts payable 1,566.3 1,728.2 Inventories 1,497.2 1,792.8 Other current liabilities 2,149.1 1,977.1 Other current assets 393.2 404.7 Long-term debt 7,551.4 8,075.3 PP&E, net 3,474.6 3,293.4 Pension/Postretirement 651.7 670.3 Goodwill and intangibles 11,641.7 11,693.4 Other liabilities 1,225.5 1,249.7 Other assets 1,086.2 983.3 Total equity 8,072.2 7,258.6 Total assets $21,846.6 $21,464.3 Total liab. and equity $21,846.6 $21,464.3 Selected Cash Flow items (millions, unaudited) 2023 2022 (unaudited) 2023 2022 Cash from op. activities $2,411.8 $1,788.4 Total Debt/Total Capital 50.3% 54.2% Depreciation 616.7 618.5 Net Debt/Total Capital 47.4% 52.4% Amortization 306.9 320.2 Net Debt/EBITDA(*) 2.4 3.2 Capital expenditures 774.8 712.8 Net Debt/Adjusted EBITDA(*) 2.3 2.9 December 31 December 31 Twelve Months Ended Selected Balance Sheet measures December 31 December 31

GRAPHIC

Non-GAAP financial measures 15 (millions, except percent and per share) Net sales Reported GAAP net sales $3,938.4 $3,671.2 $15,320.2 $14,187.8 Effect of foreign currency translation 17.0 60.0 (44.8) (94.4) Non-GAAP fixed currency sales 3,955.4 3,731.2 15,275.4 14,093.4 Effect of acquisitions and divestitures (34.3) (27.6) (113.4) (123.7) Non-GAAP organic sales $3,921.1 $3,703.6 $15,162.0 $13,969.7 Cost of sales Reported GAAP cost of sales $2,284.4 $2,254.9 $9,154.9 $8,831.0 Special (gains) and charges 5.3 8.2 22.5 69.9 Non-GAAP adjusted cost of sales $2,279.1 $2,246.7 $9,132.4 $8,761.1 Gross profit Reported GAAP gross profit $1,654.0 $1,416.3 $6,165.3 $5,356.8 Special (gains) and charges 5.3 8.2 22.5 69.9 Non-GAAP adjusted gross profit $1,659.3 $1,424.5 $6,187.8 $5,426.7 Gross margin Reported GAAP gross margin 42.0 % 38.6 % 40.2 % 37.8 % Non-GAAP adjusted gross margin 42.1 % 38.8 % 40.4 % 38.2 % Fourth Quarter Ended Tw elve Months Ended December 31 December 31 2023 2022 2023 2022

GRAPHIC

Non-GAAP financial measures 16 (millions, except percent and per share) Operating income Reported GAAP operating income $590.0 $399.2 $1,992.3 $1,562.5 Special (gains) and charges at public currency rates 34.5 103.2 133.9 210.4 Non-GAAP adjusted operating income 624.5 502.4 2,126.2 1,772.9 Effect of foreign currency translation 4.6 14.8 (5.8) (13.1) Non-GAAP adjusted fixed currency operating income 629.1 517.2 2,120.4 1,759.8 Effect of acquisitions and divestitures (1.1) - (2.9) (0.4) Non-GAAP organic operating income $628.0 $517.2 $2,117.5 $1,759.4 Operating income margin Reported GAAP operating income margin 15.0 % 10.9 % 13.0 % 11.0 % Non-GAAP adjusted fixed currency operating income margin 15.9 % 13.9 % 13.9 % 12.5 % Non-GAAP organic operating income margin 16.0 % 14.0 % 14.0 % 12.6 % Other (income) expense Reported GAAP other (income) expense ($17.9) $8.1 ($59.9) ($24.5) Special (gains) and charges - 25.8 - 50.6 Non-GAAP adjusted other (income) expense ($17.9) ($17.7) ($59.9) ($75.1) Net Income attributable to Ecolab Reported GAAP net income attributable to Ecolab $405.2 $264.4 $1,372.3 $1,091.7 Special (gains) and charges, after tax 30.6 101.5 109.2 207.3 Discrete tax net expense (benefit) 8.9 (2.3) 11.2 (11.8) Non-GAAP adjusted net income attributable to Ecolab $444.7 $363.6 $1,492.7 $1,287.2 Tw elve Months Ended December 31 December 31 2023 2022 Fourth Quarter Ended 2023 2022

GRAPHIC

Non-GAAP financial measures 17 (millions, except percent and per share) Diluted EPS attributable to Ecolab Reported GAAP diluted EPS $1.41 $0.93 $4.79 $3.81 Special (gains) and charges, after tax 0.11 0.35 0.38 0.72 Discrete tax net expense (benefit) 0.03 (0.01) 0.04 (0.04) Non-GAAP adjusted diluted EPS $1.55 $1.27 $5.21 $4.49 Provision for Income Taxes Reported GAAP tax rate 23.6 % 16.2 % 20.6 % 17.5 % Special gains and charges (0.8) 1.5 (0.1) 0.5 Discrete tax items (1.5) 0.5 (0.6) 0.7 Non-GAAP adjusted tax rate 21.3 % 18.2 % 19.9 % 18.7 % 2023 2022 2023 2022 Fourth Quarter Ended Tw elve Months Ended December 31 December 31

GRAPHIC

Non-GAAP financial measures 18 EBITDA (trailing tw elve months ended) Net income including non-controlling interest $1,393.0 $1,108.9 Provision for income taxes 362.5 234.5 Interest expense, net 296.7 243.6 Depreciation 616.7 618.5 Amortization 306.9 320.2 EBITDA $2,975.8 $2,525.7 Special (gains) and charges impacting EBITDA 133.9 261.0 Adjusted EBITDA $3,109.7 $2,786.7 Fourth Quarter Ended December 31 2023 2022

GRAPHIC

Non-GAAP financial measures 19 (millions) Fixed Currency Impact of Acquisitions and Divestitures Organic Fixed Currency Impact of Acquisitions and Divestitures Organic Net Sales Global Industrial $1,871.3 ($4.5) $1,866.8 $1,808.2 $ - $1,808.2 Global Institutional & Specialty 1,290.1 (16.0) 1,274.1 1,139.1 - 1,139.1 Global Healthcare & Life Sciences 410.1 - 410.1 413.1 - 413.1 Other 370.1 - 370.1 343.2 - 343.2 Corporate 13.8 (13.8) - 27.6 (27.6) 0.0 Subtotal at fixed currency rates 3,955.4 (34.3) 3,921.1 3,731.2 (27.6) 3,703.6 Currency impact (17.0) (60.0) Consolidated reported GAAP net sales $3,938.4 $3,671.2 Operating Income (loss) Global Industrial $322.2 $0.2 $322.4 $272.5 $ - $272.5 Global Institutional & Specialty 238.7 0.3 239.0 169.3 - 169.3 Global Healthcare & Life Sciences 48.3 - 48.3 64.2 - 64.2 Other 68.6 - 68.6 57.9 - 57.9 Corporate (48.7) (1.6) (50.3) (46.7) - (46.7) Subtotal at fixed currency rates 629.1 (1.1) 628.0 517.2 - 517.2 Special (gains) and charges at fixed currency rates 34.6 104.7 Reported OI at fixed currency rates 594.5 412.5 Currency impact (4.5) (13.3) Consolidated reported GAAP operating income $590.0 $399.2 Fourth Quarter Ended December 31 2023 2022

GRAPHIC

Non-GAAP financial information 20 Non-GAAP Financial Information: This communication and certain of the accompanying tables include financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (“GAAP”). These non-GAAP financial measures include: • fixed currency sales • organic sales, formerly known as acquisition adjusted fixed currency sales • adjusted cost of sales • adjusted gross profit • adjusted gross margin • fixed currency operating income • adjusted operating income • adjusted fixed currency operating income • adjusted fixed currency operating income margin • organic operating income, formerly known as acquisition adjusted fixed currency operating income • organic operating income margin, formerly known as acquisition adjusted fixed currency operating income margin • adjusted tax rate • adjusted net income attributable to Ecolab • adjusted diluted earnings per share • EBITDA • Adjusted EBITDA We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

GRAPHIC

Non-GAAP financial information (cont.) 21 Non-GAAP Financial Information (Continued): Our non-GAAP financial measures for adjusted cost of sales, adjusted gross margin, adjusted gross profit and adjusted operating income exclude the impact of special (gains) and charges and our non-GAAP financial measures for adjusted tax rate, adjusted net income attributable to Ecolab and adjusted diluted earnings per share further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges. EBITDA is defined as the sum of net income including non-controlling interest, provision for income taxes, net interest expense, depreciation and amortization, and adjusted EBITDA further adds special (gains) and charges impacting EBITDA. EBITDA and adjusted EBITDA are used in our net debt to EBITDA and net debt to adjusted EBITDA ratios, which we view as important indicators of the operational and financial health of our organization. We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this release are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2023. We also provide our segment results based on public currency rates for informational purposes. Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to the Company’s reportable segments. Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude the impact of special (gains) and charges, the results of our acquired businesses from the first twelve months post acquisition and the results of divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months and for a small set of products with limited suppliers over the next few years. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures. These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in this news release. Reconciliations of our non-GAAP measures are included in the following “Non-GAAP Financial Measures” tables of this communication. We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this news release) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information.

v3.24.0.1
Document and Entity Information
Feb. 13, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 13, 2024
Entity Registrant Name ECOLAB INC.
Entity Incorporation, State or Country Code DE
Securities Act File Number 1-9328
Entity Tax Identification Number 41-0231510
Entity Address, Address Line One 1 Ecolab Place
Entity Address, City or Town Saint Paul
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55102
City Area Code 800
Local Phone Number 232-6522
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000031462
Amendment Flag false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $1.00 par value
Trading Symbol ECL
Security Exchange Name NYSE
Euro Notes Due 2025 [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.625% Euro Notes due 2025
Trading Symbol ECL 25
Security Exchange Name NYSE
v3.24.0.1
N-2
Feb. 13, 2024
Cover [Abstract]  
Entity Central Index Key 0000031462
Amendment Flag false
Securities Act File Number 1-9328
Document Type 8-K
Entity Registrant Name ECOLAB INC.
Entity Address, Address Line One 1 Ecolab Place
Entity Address, City or Town Saint Paul
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55102
City Area Code 800
Local Phone Number 232-6522
Entity Emerging Growth Company false

Ecolab (NYSE:ECL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ecolab Charts.
Ecolab (NYSE:ECL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ecolab Charts.